Solid Lipid Nanoparticles: A Promising Drug Delivery Technology
DOI:
https://doi.org/10.37285/ijpsn.2009.2.2.3Abstract
One of the situations in the treatment of disease is the delivery of efficacious medication of appropriate concentration to the site of action in a controlled and continual manner. Nanoparticle represents an important particulate carrier system, developed accordingly. Nanoparticles are solid colloidal particles ranging in size from 1 to 1000 nm and composed of macromolecular material. Nanoparticles could be polymeric or lipidic (SLNs). Industry estimates suggest that approximately 40% of lipophilic drug candidates fail due to solubility and formulation stability issues, prompting significant research activity in advanced lipophile delivery technologies. Solid lipid nanoparticle technology represents a promising new approach to lipophile drug delivery. Solid lipid nanoparticles (SLNs) are important advancement in this area. The bioacceptable and biodegradable nature of SLNs makes them less toxic as compared to polymeric nanoparticles. Supplemented with small size which prolongs the circulation time in blood, feasible scale up for large scale production and absence of burst effect makes them interesting candidates for study. In this present review this new approach is discussed in terms of their preparation, advantages, characterization and special features.
Downloads
Download data is not yet available.
Metrics
Metrics Loading ...
Keywords:
Nanotechnology, Colloidal carriers, Solid lipid nanoparticles, Liposomes
Downloads
Published
2009-08-31
How to Cite
1.
S. Pragati, S. Kuldeep, S. Ashok, M. Satheesh. Solid Lipid Nanoparticles: A Promising Drug Delivery Technology. Scopus Indexed [Internet]. 2009 Aug. 31 [cited 2024 May 18];2(2):509-16. Available from: https://www.ijpsnonline.com/index.php/ijpsn/article/view/452
Issue
Section
Review Articles
References
Ahlin P. Optimization of procedure parameters and physical stability of solid lipid nanoparticles in dispersions. Acta Pharm. 48: 257-267 (1998).
Almeida AJ, Runge S, and Müller, RH. Peptide-loaded solid lipid nanoparticles (SLN): influence of production parameters. Int. J. Pharm. 149: 255-265 (1997).
Bocca C, Caputo O, Cavalli R, Gabriel L, Miglietta A, and Gasco MR. Phagocytic uptake of fluorescent stealth and non-stealth solid lipid nanoparticles. Int. J. Pharm. 175: 185-193 (1998).
Cavalli R, Bargoni A, Podio V, Muntoni E, Zara GP, and Gasco MR. Duodenal administration of solid lipid nanoparticles loaded with different percentages of tobramycin. J Pharm. Sci. 92: 1085 – 1094 (2003).
Cavalli R, Caputo O, and Gasco MR. Preparation and characterization of solid lipid nanospheres containing paclitaxel. European J. Pharm. Sci. 10: 305-309 (2000).
Cavalli R, Gasco MR, Chetoni P, Burgalassi S, and Saettone MF. Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin. Int. J. Pharm. 238: 241 – 245 (2002).
Cavalli R, Peira E, Caputo O, and Gasco MR. Solid lipid nanoparticles as carriers of hydrocortisone and progesterone complexes with -cyclodextrin. Int. J. Pharm. 59-69 (1999).
Cavalli R. The effect of the components of microemulsions on both size and crystalline structure of solid lipid nanoparticles (SLN) containing a number of model molecules. Pharmazie. 53: 392-396 (1998).
Cavalli R., Marengo E, Rodriguez L, and Gasco, MR. Effects of some experimental factors on the production process of solid lipid nanoparticles. European J. Pharm. & Biopharm. 43: 110-115 (1996).
Chen DB, Yang TZ, Lu WL, and Zhang Q. In vitro study of two types of long circulating solid lipid nanoparticles containing paclitaxel. Chem. & Pharm. Bulletin. 49:1444-1447 (2001).
Domb AJ. Long acting injectable oxytetracycline-liposphere formulation. Int. J. Pharm. 124: 271-278 (1995).
Dubes A. et al. Scanning electron microscopy and atomic force imaging of solid lipid nanoparticles derived from amphiphilic cyclodextrins. European J. Pharm. & Biopharm. 55: 279-282 (2003).
Eldem T, Speiser P, and Hincal A. Optimization of spray-dried and congealed lipid micropellets and characterization of their surface morphology by scanning electron microscopy. Pharmaceutical Research 8: 47-54 (1991).
Freitas C, and Müller RH. Stability determinatin of solid lipid nanoparticles (SLN) in aqueous dispersion after addition of electrolyte. J. Microencap. 16: 59-71 (1999).
Fundarò A. Non-stealth and stealth solid lipid nanoparticles carrying doxorubicin: pharmacokinetics and tissue distribution after i.v. administration to rats. PharmacologicalResearch 42; 337-343 (2000).
Gohla SH, and Dingler A. Scaling up feasibility of the production of solid lipidnanoparticles (SLN). Pharmazie. 56: 61-63 (2001).
Hu FQ, Hong Y, and Yuan H. Preparation and characterization of solid lipid nanoparticles containing peptide. Int. J. Pharm. 273: 29-35 (2004).
Jenning V., Lippacher, A., and Gohla, S. H. Medium scale production of solid lipid nanoparticles (SLN) by high pressure homogenisation. J Microencap. 19: 1-10 (2002)
Jores K., Mehnert, W., Drechsler, M., Bunjes, H., Johann, C., and Mäder, K. Investigations on the structure of solid lipid nanoparticles (SLN) and oil-loaded solid lipid nanoparticles by photon correlation spectroscopy, field-flow fractionation and transmission electron microscopy. J. Contr. Release 95: 217-227 (2004).
Karanth et.al. Nanotechnology in brain targeting. Int. J. Pharm. Sci. and nanotech. 1: 10-21 (2008).
Kristl J, et al. Interactions of solid lipidnanoparticles with model membranes and leukocytes studied by EPR. Int. J. Pharm. 256: 133-140 (2003).
Lim SJ, and Kim CK. Formulation parameters determining the physiochemical characteristics of solid lipid nanoparticles loaded with all-trans retinoic acid. Int. J. Pharm. 243: 135-146 (2002).
Maa YF, and Hsu C. Liquid-liquid emulsification by rotor/stator homogenization. J Contr. Release 38: 219-228 (1996).
Marengo E. et al. Scale-up of the preparation process of solid lipid nanospheres. Part I. Int. J. Pharm. 205: 3 – 13 (2000).
Mehnert W, and Mäder K. Solid lipid nanoparticles: production, characterization and applications. Advanced Drug Delivery Reviews. 47: 165-196 (2001).
Miglietta A. et al. Cellular uptake and cytotoxicity of solid lipid nanospheres (SLN) incorporating doxorubicin or paclitaxel. Int. J. Pharm. 210: 61 – 67 (2000).
Morel S, Ugazio E, Cavalli R, and Gasco MR. Thymopentin in solid lipidnanoparticles. Int. J. Pharm. 132: 259-261(1996).
Mühlen A, and Mehnert W. Drug release and release mechanism of prednisolone loaded solid lipid nanoparticles. Pharmazie 53: 552 (1998).
Müller RH, Maassen S, Schwarz C, and Mehnert, W. Solid lipid nanoparticles (SLN) as potential carrier for human use: interaction with human granulocytes. J. Contr. Release 47: 261-269 (1997).
Müller RH, Mäder, and Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery – a review of the state of the art. European J. Pharm. & Biopharm. 50: 161-177 (2000).
Runge S, Mehnert W, and Müller RH. SLN (Solid Lipid Nanoparticles), a novel formulation for the oral administration of drugs. European J Pharm. Sci. 4: S132 (1996).
Schwarz C., Mehnert, W., Lucks, J. S., and Müller, R. H. Solid lipid nanoparticles (SLN) for controlled drug delivery: I. Production, characterization and sterilization. J. Contr. Rel. 30: 83-96 (1994).
Siekmann B., and Westesen, K. Investigations on solid lipid nanoparticles prepared by precipitation in o/w emulsions. European J Pharm. & Biopharm. 43: 104-109 (1996).
Sjöström B, and Bergenstahl B. Preparation of submicron drug nanoparticles in lecithin stabilized o/w emulsions. Int. J. Pharm. 88: 53-62 (1992).
Tabatt K. Transfection with different colloidal systems: comparison of solid lipid nanoparticles and liposomes. J. Contr.Rel. 97; 321-332 (2004).
Westesen K, and Siekmann B. Investigation of the gel formation of phospholipidstabilized solid lipid nanoparticles. Int. J. Pharm. 151: 35-45 (1997).
Westesen K, Bunjes H, and Koch MHJ. Physiochemical characterization of lipid nanoparticles and evaluation of their drug loading capacity and sustained release potential. J. Contr. Rel. 48: 223-236 (1997).
Westesen K, Siekmann B, and Koch MHJ. Investigations on the physical state of lipid nanoparticles by synchrotron radiation X-ray diffraction. Int. J. Pharm. 93: 189-199 (1993).
Zara GP, et al. Bargoni, Pharmacokinetics and tissue distribution of idarubicin-loaded solid lipid nanoparticles after duodenal administration to rats. J Pharm. Sci. 91: 1324 – 1333 (2002).
Zimmermann E, Muller RH. Electrolyte- and pH-stabilities of aqueous solid lipid nanoparticle (SLN) dispersions in artificial gastrointestinal media. European J Pharm. & Biopharm 52(2): 203-10 (2001).
Almeida AJ, Runge S, and Müller, RH. Peptide-loaded solid lipid nanoparticles (SLN): influence of production parameters. Int. J. Pharm. 149: 255-265 (1997).
Bocca C, Caputo O, Cavalli R, Gabriel L, Miglietta A, and Gasco MR. Phagocytic uptake of fluorescent stealth and non-stealth solid lipid nanoparticles. Int. J. Pharm. 175: 185-193 (1998).
Cavalli R, Bargoni A, Podio V, Muntoni E, Zara GP, and Gasco MR. Duodenal administration of solid lipid nanoparticles loaded with different percentages of tobramycin. J Pharm. Sci. 92: 1085 – 1094 (2003).
Cavalli R, Caputo O, and Gasco MR. Preparation and characterization of solid lipid nanospheres containing paclitaxel. European J. Pharm. Sci. 10: 305-309 (2000).
Cavalli R, Gasco MR, Chetoni P, Burgalassi S, and Saettone MF. Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin. Int. J. Pharm. 238: 241 – 245 (2002).
Cavalli R, Peira E, Caputo O, and Gasco MR. Solid lipid nanoparticles as carriers of hydrocortisone and progesterone complexes with -cyclodextrin. Int. J. Pharm. 59-69 (1999).
Cavalli R. The effect of the components of microemulsions on both size and crystalline structure of solid lipid nanoparticles (SLN) containing a number of model molecules. Pharmazie. 53: 392-396 (1998).
Cavalli R., Marengo E, Rodriguez L, and Gasco, MR. Effects of some experimental factors on the production process of solid lipid nanoparticles. European J. Pharm. & Biopharm. 43: 110-115 (1996).
Chen DB, Yang TZ, Lu WL, and Zhang Q. In vitro study of two types of long circulating solid lipid nanoparticles containing paclitaxel. Chem. & Pharm. Bulletin. 49:1444-1447 (2001).
Domb AJ. Long acting injectable oxytetracycline-liposphere formulation. Int. J. Pharm. 124: 271-278 (1995).
Dubes A. et al. Scanning electron microscopy and atomic force imaging of solid lipid nanoparticles derived from amphiphilic cyclodextrins. European J. Pharm. & Biopharm. 55: 279-282 (2003).
Eldem T, Speiser P, and Hincal A. Optimization of spray-dried and congealed lipid micropellets and characterization of their surface morphology by scanning electron microscopy. Pharmaceutical Research 8: 47-54 (1991).
Freitas C, and Müller RH. Stability determinatin of solid lipid nanoparticles (SLN) in aqueous dispersion after addition of electrolyte. J. Microencap. 16: 59-71 (1999).
Fundarò A. Non-stealth and stealth solid lipid nanoparticles carrying doxorubicin: pharmacokinetics and tissue distribution after i.v. administration to rats. PharmacologicalResearch 42; 337-343 (2000).
Gohla SH, and Dingler A. Scaling up feasibility of the production of solid lipidnanoparticles (SLN). Pharmazie. 56: 61-63 (2001).
Hu FQ, Hong Y, and Yuan H. Preparation and characterization of solid lipid nanoparticles containing peptide. Int. J. Pharm. 273: 29-35 (2004).
Jenning V., Lippacher, A., and Gohla, S. H. Medium scale production of solid lipid nanoparticles (SLN) by high pressure homogenisation. J Microencap. 19: 1-10 (2002)
Jores K., Mehnert, W., Drechsler, M., Bunjes, H., Johann, C., and Mäder, K. Investigations on the structure of solid lipid nanoparticles (SLN) and oil-loaded solid lipid nanoparticles by photon correlation spectroscopy, field-flow fractionation and transmission electron microscopy. J. Contr. Release 95: 217-227 (2004).
Karanth et.al. Nanotechnology in brain targeting. Int. J. Pharm. Sci. and nanotech. 1: 10-21 (2008).
Kristl J, et al. Interactions of solid lipidnanoparticles with model membranes and leukocytes studied by EPR. Int. J. Pharm. 256: 133-140 (2003).
Lim SJ, and Kim CK. Formulation parameters determining the physiochemical characteristics of solid lipid nanoparticles loaded with all-trans retinoic acid. Int. J. Pharm. 243: 135-146 (2002).
Maa YF, and Hsu C. Liquid-liquid emulsification by rotor/stator homogenization. J Contr. Release 38: 219-228 (1996).
Marengo E. et al. Scale-up of the preparation process of solid lipid nanospheres. Part I. Int. J. Pharm. 205: 3 – 13 (2000).
Mehnert W, and Mäder K. Solid lipid nanoparticles: production, characterization and applications. Advanced Drug Delivery Reviews. 47: 165-196 (2001).
Miglietta A. et al. Cellular uptake and cytotoxicity of solid lipid nanospheres (SLN) incorporating doxorubicin or paclitaxel. Int. J. Pharm. 210: 61 – 67 (2000).
Morel S, Ugazio E, Cavalli R, and Gasco MR. Thymopentin in solid lipidnanoparticles. Int. J. Pharm. 132: 259-261(1996).
Mühlen A, and Mehnert W. Drug release and release mechanism of prednisolone loaded solid lipid nanoparticles. Pharmazie 53: 552 (1998).
Müller RH, Maassen S, Schwarz C, and Mehnert, W. Solid lipid nanoparticles (SLN) as potential carrier for human use: interaction with human granulocytes. J. Contr. Release 47: 261-269 (1997).
Müller RH, Mäder, and Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery – a review of the state of the art. European J. Pharm. & Biopharm. 50: 161-177 (2000).
Runge S, Mehnert W, and Müller RH. SLN (Solid Lipid Nanoparticles), a novel formulation for the oral administration of drugs. European J Pharm. Sci. 4: S132 (1996).
Schwarz C., Mehnert, W., Lucks, J. S., and Müller, R. H. Solid lipid nanoparticles (SLN) for controlled drug delivery: I. Production, characterization and sterilization. J. Contr. Rel. 30: 83-96 (1994).
Siekmann B., and Westesen, K. Investigations on solid lipid nanoparticles prepared by precipitation in o/w emulsions. European J Pharm. & Biopharm. 43: 104-109 (1996).
Sjöström B, and Bergenstahl B. Preparation of submicron drug nanoparticles in lecithin stabilized o/w emulsions. Int. J. Pharm. 88: 53-62 (1992).
Tabatt K. Transfection with different colloidal systems: comparison of solid lipid nanoparticles and liposomes. J. Contr.Rel. 97; 321-332 (2004).
Westesen K, and Siekmann B. Investigation of the gel formation of phospholipidstabilized solid lipid nanoparticles. Int. J. Pharm. 151: 35-45 (1997).
Westesen K, Bunjes H, and Koch MHJ. Physiochemical characterization of lipid nanoparticles and evaluation of their drug loading capacity and sustained release potential. J. Contr. Rel. 48: 223-236 (1997).
Westesen K, Siekmann B, and Koch MHJ. Investigations on the physical state of lipid nanoparticles by synchrotron radiation X-ray diffraction. Int. J. Pharm. 93: 189-199 (1993).
Zara GP, et al. Bargoni, Pharmacokinetics and tissue distribution of idarubicin-loaded solid lipid nanoparticles after duodenal administration to rats. J Pharm. Sci. 91: 1324 – 1333 (2002).
Zimmermann E, Muller RH. Electrolyte- and pH-stabilities of aqueous solid lipid nanoparticle (SLN) dispersions in artificial gastrointestinal media. European J Pharm. & Biopharm 52(2): 203-10 (2001).
